Bioinoculant-induced plant resistance is modulated by interactions with resident soil microbes.

Background: Entomopathogenic fungi are increasingly used as bio-inoculants to enhance crop growth and resistance. When applied to rhizosphere soil, they interact with resident soil microbes, which can affect their ability to colonize and induce resistance in plants as well as modify the structure of the resident soil microbiome, either directly through interactions in the rhizosphere or indirectly, mediated by the plant. The extent to which such direct versus indirect interactions between bio-inoculants and soil microbes impact microbe-induced resistance in crops remains unclear.

Practical algebraic calculus and Nullstellensatz with the checkers Pacheck and Pastèque and Nuss-Checker.

Unlabelled: Automated reasoning techniques based on computer algebra have seen renewed interest in recent years and are for example heavily used in formal verification of arithmetic circuits. However, the verification process might contain errors. Generating and checking proof certificates is important to increase the trust in automated reasoning tools.

The imprint of microbe-induced plant resistance in plant-associated insects.

Beneficial microbes induce resistance in plants (MIR), imposing both lethal and sublethal effects on herbivorous insects. We argue that herbivores surviving MIR carry metabolic and immunological imprints of MIR with cascading effects across food webs. We propose that incorporating such cascading effects will strongly enhance the current MIR research framework.

In vivo effects of the alpha-synuclein misfolding inhibitor minzasolmin supports clinical development in Parkinson's disease.

Direct targeting of alpha-synuclein (ASYN) has emerged as a disease-modifying strategy for Parkinson's disease and other synucleinopathies which is being approached using both small molecule compounds and ASYN-targeted biologics. Minzasolmin (UCB0599) is an orally bioavailable and brain-penetrant small molecule ASYN misfolding inhibitor in clinical development as a disease-modifying therapeutic for Parkinson's disease. Herein the results of preclinical evaluations of minzasolmin that formed the basis for subsequent clinical development are described.